Background: LPA and its receptors represent two key players in regulating cancer progression. Recent findings suggest that upregulation of lysophosphatidic acid receptor 2(LPAR2) may play a role in carcinogenesis. But there are few studies on the relationship between LPAR2 and tumor immune microenvironment.
Methods: In this study, we analyzed LPAR2 expression in pan tumors via the Oncomine, Tumor Immune Estimation Resource (TIMER), and UALCAN. We investigated the influence of LPAR2 on clinical prognosis from Kaplan-Meier plotter (K-M plotter), Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN and Human Protein Atlas (HPA). We also examined the relationship of
expression levels of LPAR2 and clinical and molecular criteria in HNSC and KIRC by UALCAN. Then we explored the relationship between LPAR2 expression and prognosis in HNSC and KIRC patients with different clinical characteristics via K-M plotter. The correlations between LPAR2 and cancer immune infiltrates was examined via TIMER. In addition, correlations between the expression of LPAR2 and gene markers of immune infiltrates were analyzed by TIMER and GEPIA. We also used the cBioPortal to calculate mutations, methylations and altered neighbor genes of LPAR2.
Results: We found that LPAR2 different expression was significantly related with the outcome of multiple types of cancer from The Cancer Genome Atlas (TCGA), particularly in head and neck squamous cell carcinoma (HNSC) and kidney renal clear cell carcinoma (KIRC). Furthermore, high expression levels of LPAR2 were found to be significantly associated with a variety of immune markers in particular immune cell subsets in HNSC and KIRC.
Conclusions: Our finding indicates that high LPAR2 expression playing significantly different prognostic roles in HNSC and KIRC, might be due to associate with different immune markers. And LPAR2 is correlated with tumor immune cell infiltration and is a valuable prognostic biomarker in HNSC and KIRC patients.